Company / SG&A Expense
CorVel Corporation SG&A Expense History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$88.9M
FY2024
5-year range
$67.6M / $88.9M
FY2020-FY2024
Trend
+16.1%
vs FY2023
Sector context
#131 of 152
Health Care
What the data says
CorVel Corporation's sg&a expense of $89M is lower than 86% of companies in the Health Care sector (FY2024). SG&A Expense has increased for 4 consecutive years, from $64M in FY2020 to $89M in FY2024.
Based on SEC 10-K filings.
$89M in FY2024 with a 5-year CAGR of +6.4%.
Increased from $74M to $89M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +9.6%
- 5-Year CAGR
- +6.4%
- 10-Year CAGR
- -
Sector benchmark
Top 14% in Health CareTop 14% of 152This company $88.9M Sector average $182.7B
▼
-100.0% below sector average
Key checks
Key Insights
- CorVel Corporation's sg&a expense has grown for 4 consecutive years.
- 5-year CAGR of +6.4%, indicating consistent growth.
- In FY2024, sg&a expense increased 16.1% year-over-year.
- Ranks #131 out of 152 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $88.9M | +16.1% |
| FY2023 | $76.6M | +3.9% |
| FY2022 | $73.7M | +9.0% |
| FY2021 | $67.6M | +4.9% |
| FY2020 | $64.4M | -1.2% |
| FY2019 | $65.2M | +3.0% |
| FY2018 | $63.3M | +6.6% |
| FY2017 | $59.4M | +3.7% |
| FY2016 | $57.2M | -2.1% |
As of FY2024 · SEC 10-K · Updated Mar 29, 2026